Cytek Biosciences Inc (CTKB)
Liquidity ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 6.97 | 7.20 | 7.93 | 7.53 | 9.26 | 10.70 | 10.47 | 10.26 |
| Quick ratio | 5.66 | 5.85 | 6.50 | 6.05 | 7.95 | 9.19 | 9.13 | 9.18 |
| Cash ratio | 4.67 | 4.91 | 5.58 | 5.29 | 6.96 | 8.23 | 8.26 | 8.47 |
Cytek Biosciences Inc has consistently maintained strong liquidity ratios over the past few quarters. The current ratio, which measures the company's ability to cover its short-term liabilities with its current assets, has been consistently above 6. This indicates that Cytek Biosciences Inc has a healthy level of current assets to meet its short-term obligations.
Similarly, the quick ratio, which excludes inventory from current assets to provide a more stringent measure of liquidity, has also been consistently high, above 5 in most quarters. This suggests that the company has a sufficient level of highly liquid assets to cover its short-term liabilities without relying on inventory.
The cash ratio, which is the most conservative liquidity ratio and measures the company's ability to cover its current liabilities with its cash and cash equivalents, has also been robust, consistently above 4. This indicates that Cytek Biosciences Inc has a strong ability to meet its short-term obligations using its cash resources alone.
Overall, the liquidity position of Cytek Biosciences Inc appears sound, with strong current, quick, and cash ratios across the quarters, reflecting the company's ability to manage its short-term financial obligations effectively.
Additional liquidity measure
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||
|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 358.35 | 403.71 | 429.09 | 459.72 | 359.63 | 359.97 | 327.61 | 294.49 |
The cash conversion cycle of Cytek Biosciences Inc has shown some fluctuations over the past eight quarters. The cycle measures the time it takes for the company to convert its investments in inventory and other resources into cash flows from sales.
From March 2022 to June 2023, the cash conversion cycle has shown an increasing trend, indicating that the company has been taking longer to convert its resources into cash. This may suggest some inefficiencies in inventory management or delays in collecting accounts receivable.
The peak in the cash conversion cycle was observed in March 2023 at 459.72 days, which may raise concerns about the company's liquidity and working capital management during that period.
It is important for Cytek Biosciences Inc to closely monitor its cash conversion cycle and work towards optimizing it to ensure efficient use of resources and improved cash flow generation in the future.